Amicus Therapeutics, Inc. (FOLD)

NASDAQ: FOLD · IEX Real-Time Price · USD
11.78
-0.08 (-0.67%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.

Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics, Inc.
Amicus Therapeutics logo
Country United States
Founded 2002
IPO Date May 31, 2007
Industry Biotechnology
Sector Healthcare
Employees 517
CEO Bradley L. Campbell M.B.A.

Contact Details

Address:
3675 Market Street
Philadelphia, Pennsylvania 19104
United States
Phone (215) 921-7600
Website amicusrx.com

Stock Details

Ticker Symbol FOLD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001178879
CUSIP Number 03152W109
ISIN Number US03152W1099
Employer ID 20-0422823
SIC Code 2834

Key Executives

Name Position
Bradley L. Campbell M.B.A. Chief Executive Officer, President and Director
Ellen S. Rosenberg Chief Legal Officer and Corporate Secretary
David M. Clark Chief People Officer
Dr. Jeffrey P. Castelli Chief Development Officer
Simon Nicolas Reade Harford Chief Financial Officer
Samantha Prout Chief Accounting Officer and Controller
Dr. Jill Weimer Ph.D. Chief Science Officer
Andrew Faughnan Senior Director of Investor Relations
Patrik S. Florencio Esq. Global Chief Compliance and Risk Officer
Diana Moore Head of Global Corporate Communications

Latest SEC Filings

Date Type Title
Mar 15, 2024 144 Filing
Mar 5, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 1, 2024 144 Filing
Mar 1, 2024 144 Filing
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 15, 2024 144 Filing
Feb 15, 2024 144 Filing
Feb 15, 2024 144 Filing